Fly News Breaks for December 3, 2019
Dec 3, 2019 | 15:57 EDT
After speaking with CEO Matt Kapusta for a fireside chat today, Piper Jaffray analyst Danielle Brill says uniQure is a name that "investors need to own." The analyst reiterates an Overweight rating on the shares with an $80 price target. The company is approaching catalysts for AMT-061 in hemophilia B and first in-human Huntington's disease data with AMT-130 expected in 2020, Brill tells investors in a research note. She believes uniQure's "deep" pipeline and in-house manufacturing capabilities differentiate it from other gene therapy companies.
News For QURE From the Last 2 Days
There are no results for your query QURE